Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "Synergy Pharmaceuticals, Inc." (SGYP) Report Updated: Nov 23, 2015 | Print This Page

Get more stock ratings by Louis Navellier

"Synergy Pharmaceuticals, Inc." (SGYP)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Biotechnology
Competitors: AVXL, EGRX, ZIOP, NBIX

Stock Analysis

Rating: Monthly View

November December January February March April May June July August September October

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

"Synergy Pharmaceuticals, Inc."© quotemedia

Company Profile

Synergy Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the development of drugs to treat gastrointestinal disorders and diseases in the United States. Its lead product candidate is Plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, which is in Phase II/III clinical trials to treat gastrointestinal disorders, primarily chronic constipation. The company also develops Plecanatide for the treatment of constipation-predominant-irritable bowel syndrome. In addition, it develops SP-333, a second generation GC-C receptor analog that is in pre-clinical development stage for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis and Crohnís disease. The company is headquartered in New York, New York.

Recent News: "Synergy Pharmaceuticals, Inc."